ALEC logo

ALECTOR INC

ALECNASDAQ
πŸ† #3050 by market capUS Equity
β€”β€”
Quote unavailable
πŸ””
Track ALEC
Get earnings, price moves & breaking news on Telegram
Track
24hβ€”
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$348M
Small Cap
πŸ“ˆRevenue Growth (YoY)
-79.1%
Declining
πŸ“ŠGross Margin
100.0%
High
πŸ’΅FCF Margin
-86.5%
Thin
βš–οΈP/S Ratio
2.0x
Cheap
Otter Score
β€”
Insufficient data
No chart data available for ALEC.

Trading Snapshot

Day Range
β€”
52-Week Range
$1.09 – $2.84
Volume (shares)
β€”
Avg Volume (shares)
β€”
Shares Outstanding
148.9M
Next Earnings
β€”

Fundamentals Snapshot

Annual Revenue
$21M
Last Q Revenue
$163M
P/E Ratio
6.7
P/S Ratio
2.0x
EPS (TTM)
$0.37
Dividend Yield
0.00%
Dilution (1yr)
+6.6%
ALEC logo

ALECTOR INC

ALEC
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$21Mβ–Ό βˆ’79.1% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
54.1%β–Ό βˆ’163.7% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$146Mβ–² +0.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$184Mβ–Ό βˆ’20.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
103.0Mβ–² +6.6% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$30Mβ–² +$39M YoY
StockOtter Β· stockotter.space

About ALECTOR INC

Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100
Analyst data unavailable.

Latest News & Updates

News unavailable.